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TGR5 is a G protein-coupled receptor expressed in
brown adipose tissue and muscle, where its activa-
tion by bile acids triggers an increase in energy
expenditure and attenuates diet-induced obesity.
Using a combination of pharmacological and genetic
gain- and loss-of-function studies in vivo, we show
here that TGR5 signaling induces intestinal gluca-
gon-like peptide-1 (GLP-1) release, leading to im-
proved liver and pancreatic function and enhanced
glucose tolerance in obese mice. In addition, we
show that the induction of GLP-1 release in enteroen-
docrine cells by 6a-ethyl-23(S)-methyl-cholic acid
(EMCA, INT-777), a specific TGR5 agonist, is linked
to an increase of the intracellular ATP/ADP ratio and
a subsequent rise in intracellular calcium mobiliza-
tion. Altogether, these data show that the TGR5
signaling pathway is critical in regulating intestinal
GLP-1 secretion in vivo, and suggest that pharmaco-
logical targeting of TGR5 may constitute a promising
incretin-based strategy for the treatment of diabesity
and associated metabolic disorders.
INTRODUCTION
Bile acids (BAs) have evolved over the past few years from being
considered as simple lipid solubilizers to complex metabolic inte-
grators (Houten et al., 2006; Thomas et al., 2008; Zhang and Ed-
wards, 2008). Beyond the orchestration of BA, lipid, and glucose
metabolism by the nuclear receptor farnesoid X receptor (FXR),
BAs also act as signaling molecules through the BA-dedicated
G protein-coupled receptor (GPCR) TGR5 (GPR131) (Kawamata
et al., 2003; Maruyama et al., 2002). Stimulation of the TGR5
signaling pathway confers to BAs the ability to modulate energy
expenditure by controlling the activity of type 2 deiodinase and
the subsequent activation of thyroid hormone in brown adipose
tissue (BAT) and muscle. In accordance with this, pharmacolog-Cell Mical intervention with a diet containing 0.5% of cholic acid (CA)
efficiently attenuates diet-induced obesity (DIO) in mice (Wata-
nabe et al., 2006). These results have indicated that TGR5 could
be a promising target for the treatment of metabolic disorders
associated with weight gain. In addition, expression of TGR5
has recently been described in enteroendocrine L cells (Reimann
et al., 2008) and enteroendocrine cell lines, such as the STC-1
cells (Katsuma et al., 2005), which secrete the incretin glu-
cagon-like peptide-1 (GLP-1) upon nutrient intake. The thera-
peutic relevance of GLP-1 is currently well established, since
enhancement of the half-life of GLP-1 upon treatment with dipep-
tidyl peptidase 4 inhibitors (DPP4i) or activation of the GLP-1
receptor by exendin-4 derivatives (Ex-4) have been proven effica-
cious in the treatment of type 2 diabetes (Drucker, 2006; Drucker
and Nauck, 2006). Therefore, the direct stimulation of intestinal
GLP-1 release could constitute another promising GLP-1-based
therapeutic approach for the treatment of metabolic diseases.
In this context, we hypothesized that TGR5 could play a critical
in vivo role in the control of intestinal GLP-1 release and in the
maintenance of glucose homeostasis. This assumption was
investigated in vivo using a combination of gain- and loss-of-
function genetic approaches. Additionally, we identified and
explored the therapeutic properties of the semisynthetic CA
derivative, 6a-ethyl-23(S)-methyl-cholic acid (EMCA, INT-777),
a potent TGR5 agonist with no FXR activity, which could hold
promise for the treatment of diabesity.
RESULTS
TGR5 Activation Stimulates GLP-1 Release from
Enteroendocrine L Cells by Enhancing Mitochondrial
Oxidative Phosphorylation and Calcium Influx
We report here a semisynthetic CA derivative, 6a-ethyl-23(S)-
methyl-CA (EMCA, INT-777), as a selective and potent TGR5
agonist (Figures 1A and 1B). The rational for selecting this
compound was based on previous in vivo work showing that
CA induces energy expenditure via activation of TGR5 (Wata-
nabe et al., 2006), and on structure-activity studies showing
that alkyl substitutions at positions 6a and 23(S) improve the
potency and selectivity of chenodeoxycholic acid (CDCA)etabolism 10, 167–177, September 2, 2009 ª2009 Elsevier Inc. 167
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TGR5 Activation Prevents Metabolic DisordersFigure 1. Activation of TGR5 Signaling
Pathway Activates Mitochondrial Oxidative
Phosphorylation and Increases ATP/ADP
Ratio in Enteroendocrine L Cells
(A) Activity of 6a-ethyl-23(S)-methyl-cholic acid
(INT-777) and CA on TGR5 in CHO cells transiently
transfected with human TGR5 expression vector
and a Cre-Luc reporter vector. EC50 values are
expressed as percent of the activity of 10 mM of
LCA (n = 3).
(B) Chemical structure of CA and INT-777 and
respective TGR5 EC50.
(C) Intracellular cAMP levels in STC-1 cells trans-
fected with control or mTGR5 shRNA for 36 hr
and treated for 1 hr with INT-777 at the concentra-
tions indicated (n = 3).
(D) Correlation plots for liver mRNA expression of
TGR5 and CoxVI1a in the mouse BxD genetic
reference population (n = 41) as found in http://
www.genenetwork.org/ and described in the
Supplemental Experimental Procedures.
(E) Cox activity in STC-1 cells treated for 1 hr with
INT-777 at the concentration indicated. Vehicle or
adenylate cyclase inhibitor MDL-12330-A (MDL)
(1 mM) was added 15 min prior to treatment (n = 3).
(F) Oxygen consumption in STC-1 cells was
measured by using the XF24 extracellular flux
analyzer (Seahorse Bioscience). The first vertical
dotted line indicates the addition of vehicle or
MDL-12330-A (MDL) to culture medium, and the
second dotted line depicts the treatment with
INT-777 at 1 mM (n = 10).
(G) ATP/ADP ratio in STC-1 cells treated as in (E)
(n = 3).
(H) Correlation plots for liver mRNA expression of
TGR5 and Kir6.2 in the mouse BxD genetic refer-
ence population according to a similar strategy
as described (D).
(I) mRNA expression levels of TGR5, CoxIV, and
Kir6.2 in STC-1 cells transfected for 36 hr with
control or mTGR5 shRNA was measured by real-
time quantitative PCR. Target mRNA levels were
normalized to 36B4 mRNA levels (n = 3). The
data are represented as mean ± SE; Student’s
unpaired t test; *p < 0.05.toward TGR5 (Pellicciari et al., 2007; Sato et al., 2008). The addi-
tion of these alkyl substitutions to CA improved the resulting
compound’s EC50 on TGR5 by 30-fold (Figure 1B), while critically
reducing its activity on FXR (see Figure S1A available online). In
accordance with previous studies, activation of TGR5 (Katsuma
et al., 2005; Kawamata et al., 2003; Maruyama et al., 2002) by
INT-777 triggered a dose-dependent increase in intracellular
cAMP levels in enteroendocrine STC-1 cells (Figure 1C). This
induction was abrogated upon reduction of TGR5 expression
by a specific TGR5 shRNA (Figure 1C), illustrating the specificity
of the compound. The specificity of INT-777 for TGR5 was
further confirmed by its inability to activate a subset of nuclear
receptors involved in lipid and xenobiotic metabolism
(Figure S1A), as well as other GPCRs that are phylogenetically
related to TGR5 (Figures S1B and S1C).
Since we previously established a link between BAs and
energy expenditure in vivo (Watanabe et al., 2006), we specu-
lated that activation of TGR5 signaling could impact mitochon-
drial activity in a more general fashion. To find initial support168 Cell Metabolism 10, 167–177, September 2, 2009 ª2009 Elseviefor this hypothesis, we analyzed TGR5 mRNA expression via
the GeneNetwork liver mRNA database in the BxD genetic refer-
ence population (http://www.genenetwork.org/). A wide range of
variation in TGR5 mRNA expression was evident among the
different BxD mouse strains (Figure S2A). Interestingly, TGR5
mRNA expression was highly significantly correlated with the
expression of several genes encoding for subunits of complexes
involved in oxidative phosphorylation, such as cytochrome c
oxidase (Cox) (e.g., CoxVI1a; Figure 1D) and ATP synthase
(Atp6v0b, ATPase H+ transporting V0 subunit B; Atpaf2, ATP
synthase mitochondrial F1 complex assembly factor 2; Atp1a3,
ATPase Na+/K+ transporting alpha 3 polypeptide; Atp6v1b2,
ATPase H+ transporting V1 subunit B isoform 2; Figure S2B).
Consistent with this observation, treatment of STC-1 cells with
INT-777 resulted in a cAMP-dependent increase in Cox activity
(Figure 1E), which was associated with an increase in cellular
oxygen consumption (Figure 1F) and a rise in the ATP/ADP ratio
(Figure 1G). This result was confirmed in the human enteroendo-
crine cell line NCI-H716, in which INT-777 treatment increasedr Inc.
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TGR5 Activation Prevents Metabolic DisordersFigure 2. Activation of TGR5 Signaling Pathway Increases Intracellular Calcium Level and Stimulates GLP-1 Release in Enteroendocrine
L Cells
(A) Correlation plots for liver mRNA expression of TGR5 and Cav2.2 in the mouse BxD genetic reference population (n = 41) as found at http://www.genenetwork.
org/ and as described in the Supplemental Experimental Procedures.
(B and C) Intracellular calcium level in NCI-H716 cells transfected with mock vector, hTGR5 expression vector, or hTGR5 siRNA for 36 hr and treated with 1 (B) or
10 mM (C) of INT-777. The arrow represents INT-777 treatment (n = 3).
(D) Intracellular calcium level in NCI-H716 cells treated with 3 mM of INT-777 (indicated by the arrow) in the presence of vehicle or adenylate cyclase inhibitor
MDL-12330-A (MDL) (10 mM). MDL or vehicle was added 15 min prior to INT-777 treatment (n = 3).
(E) Intracellular calcium level in NCI-H716 cells treated with 1% glucose and then with 1 mM of INT-777 (n = 3).
(F) GLP-1 release in NCI-H716 cells treated with 1% glucose or 1 mM INT-777, or a combination of both agents (n = 3).
(G) GLP-1 release in STC-1 cells transfected for 36 hr with control, mTGR5 expression vector, or mTGR5 shRNA and then exposed 30 min to INT-777 at the
indicated concentration. A DPP4 inhibitor (Millipore) was added into culture medium at 0.1% (n = 3).
(H) Impact of 30 min of INT-777 treatment on GLP-1 release in STC-1 cells transfected with mTGR5 expression vector in the presence of vehicle or adenylate
cyclase inhibitor MDL-12330-A (10 mM). MDL or vehicle was added 15 min prior to INT-777 treatment. A DPP4 inhibitor (Millipore) was added into culture medium
at 0.1% (n = 3). The data are represented as mean ± SE. Student’s unpaired t test; *p < 0.05 vehicle versus INT-777 treatment; #p < 0.05 vehicle versus
MDL-12330-A treatment.ATP production in a cAMP-dependent manner (Figure S3A).
Interestingly, TGR5 expression was also strongly correlated
with that of Kir6.2, a component of the ATP-dependent potas-
sium channel (KATP) (Figure 1H). These correlations were further
corroborated by TGR5 RNA interference in STC-1 cells, which
resulted in a concomitant drop in the expression of CoxIV and
Kir6.2 mRNAs (Figure 1I).
In pancreatic b cells, it is well established that an increase in the
ATP/ADP ratio derived from glucose metabolism closes the KATP
channels, resulting in depolarization of the plasma membrane.
This membrane depolarization in turn opens calcium-gated
voltage channels (Cav), causing calcium influx. The resultant
increase in intracellular calcium then triggers the direct interac-
tion between exocytotic proteins situated in the insulin-contain-
ing granule membrane and those located in the plasma
membrane (Yang and Berggren, 2006), leading to the subsequent
release of insulin (Nichols, 2006). Recent findings support theCell Mhypothesis that KATP and Cav channels also play a pivotal role
in GLP-1 release from enteroendocrine L cells (Reimann and
Gribble, 2002; Reimann et al., 2008). Fascinatingly, in the BxD
reference population, we also found that TGR5 expression corre-
lated with the expression of Cav2.2 (Figure 2A), whose expression
was previously described in enteroendocrine cells (Reimann
et al., 2005) and which participates in calcium-stimulated insulin
release in pancreatic b cells (Yang and Berggren, 2006). Along
with this, INT-777 robustly increased calcium influx in the human
enteroendocrine cell line NCI-H716, an effect that was potenti-
ated by TGR5 overexpression and, by contrast, blunted by
TGR5 RNA interference (Figures 2B and 2C) or by the addition
of the adenylate cyclase inhibitor MDL-12330A (MDL) (Figure 2D).
In addition, the presence of glucose enhanced the TGR5-depen-
dent increase in intracellular calcium (Figure 2E). This effect was
correlated with a rise in GLP-1 release from the NCI-H716 cells
(Figure 2F), which was inhibited by MDL-12-330A (Figure S3B).etabolism 10, 167–177, September 2, 2009 ª2009 Elsevier Inc. 169
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TGR5 Activation Prevents Metabolic DisordersFigure 3. TGR5 Signaling Pathway Modulates GLP-1 Secretion In Vivo
(A) Oral glucose tolerance test (OGTT) in male TGR5-Tg mice fed for 10 weeks with HF diet and in age-matched male littermates fed with a CD or a HF diet for the
same duration. All mice were 8 weeks old at the initiation of the HF diet. Body weight of TGR5-Tg and control littermates was 37.9 ± 1.7 g and 37.0 ± 1.8 g, respec-
tively (n = 8; not statistically different). The adjacent bar graph represents the average area under the curve (AUC) (n = 8).
(B and C) Plasma levels of insulin (top panel) and GLP-1 (bottom panel) during OGTT (B) or before and after a test meal challenge (C) (n = 8).
(D) GLP-1 release from ileal explants isolated from control and TGR5-Tg male mice fed for 18 weeks with HF diet and exposed for 1 hr to the indicated concen-
trations of LCA (n = 4).
(E) Representative immunofluorescent insulin-stained pancreatic sections from TGR5-Tg male mice fed with a HF diet for 20 weeks or from male age-matched
littermates fed with a CD or a HF diet for the same duration.
(F) Distribution profile of pancreatic islets from male TGR5-Tg mice and control littermates fed with a CD or a HF diet as described in (E). Islets were counted and
sized by the ImageJ analysis software on four H&E-stained alternated pancreatic sections spaced each by 150 mM (n = 5).
(G) Insulin content in collagenase-isolated pancreatic islets from male TGR5-Tg mice and control littermates fed with a CD or a HF diet as described in (E).
(H) OGTT in TGR5/ and TGR5+/+ male mice fed with a HF diet for 8 weeks. The inset represents the average AUC. Body weight of TGR5+/+ and TGR5/ male
mice at time of analysis was 46.3 ± 3.9 g and 51.9 ± 2.0 g, respectively (n = 8; not statistically different).
(I and J) Plasma GLP-1 levels in CD-fed TGR5+/+ (I) and TGR5/ mice (J) after an oral glucose challenge, preceded 30 min before by the oral administration of
saline or INT-777 (30 mg/kg), alone or in combination with a dipeptidyl-peptidase-4 inhibitor (DPP4i, 3 mg/kg) (n = 6). The data are represented as mean ± SE.
Student’s unpaired t test; *p < 0.05, HF-fed compared to HF-fed INT-777-treated mice; and #p < 0.05, HF-fed versus CD-fed mice except for (I) and (J), where
* assessed saline- or DPP4i-treated mice versus INT-777 or INT-777 + DPP4i-treated mice, and # saline- versus DPP4i-treated mice.The TGR5-mediated GLP-1 release triggered by INT-777 was
further confirmed in the mouse enteroendocrine STC-1 cells in
which the impact of INT-777 on GLP-1 release was enhanced
by TGR5 overexpression, while being prevented either by RNA
interference (Figure 2G) or by MDL-12-330A, further underscor-
ing the cAMP dependence of TGR5-mediated GLP-1 release
(Figure 2H). Taken together, these data demonstrate that TGR5
regulates a key pathway governing the release of GLP-1 from en-
teroendocrine L cells.
TGR5 Overexpression Modulates GLP-1 Secretion
In Vivo
To further evaluate the metabolic role of enhanced TGR5
signaling, we assessed the impact of transgenic overexpression170 Cell Metabolism 10, 167–177, September 2, 2009 ª2009 Elsevieof TGR5 in vivo in the context of DIO in mice. TGR5 transgenic
mice (TGR5-Tg) were generated by oocyte injection of the bacte-
rial artificial chromosome (BAC) RP23-278N11 (Figure S4A). By
quantitative real-time PCR, TGR5-Tg mice were shown to have
integrated six copies of the RP23-278N11 BAC clone, leading
to a robust TGR5 mRNA expression, restricted to most tissues
that express TGR5 normally (Figure S4B). Glucose tolerance
was markedly improved in TGR5-Tg mice challenged for 10
weeks with a high-fat (HF) diet compared to control HF-fed litter-
mates (Figure 3A), whereas no difference was noticed in mice on
chow diet (CD) (data not shown). In contrast to our expectations,
no differences were observed in body weight gain between wild-
type and TGR5-Tg mice on CD or HF diet (Figures S5A and S5B),
demonstrating that improvement of glucose tolerance inr Inc.
Cell Metabolism
TGR5 Activation Prevents Metabolic DisordersTGR5-Tg mice could not be attributed to the confounding effects
of weight loss. The absence of weight gain in TGR5-Tg mice, in
the wake of an increase in energy expenditure (Figure S5C), was
explained by a reduction of locomotor activity (Figure S5D).
Since GLP-1 receptor knockout mice display a marked hyper-
activity (Hansotia et al., 2007), we administered the GLP-1
receptor agonist Ex-4 to wild-type mice in order to assess
whether the decrease in locomotor activity in TGR5-Tg mice
could be linked to GLP-1 secretion. Ex-4 efficiently and dose-
dependently reduced locomotor activity in mice. Interestingly,
at 1 nmol/Kg, we noticed a significant decrease in locomotor
activity while the mice were still eating properly (Figures S5E
and S5F).
Interestingly, and according to our expectations, glucose
tolerance in TGR5-Tg mice was associated with a robust GLP-
1 secretion and insulin release in response to an oral glucose
load (Figure 3B). The significance of the enhanced GLP-1 secre-
tion was underscored by the fact that measurements of plasma
GLP-1 levels were performed without preliminary oral adminis-
tration of a dipeptidyl peptidase-4 (DPP4) inhibitor to the mice.
This enhanced GLP-1 release in TGR5-Tg mice helps to explain
the decreased locomotor activity in these mice. To further inves-
tigate the impact of TGR5 overexpression on GLP-1 secretion,
the HF-fed mice were subsequently challenged with a test
meal to stimulate BA release from the gallbladder. Interestingly,
the impact of TGR5 overexpression on insulin and GLP-1 secre-
tion was more pronounced postprandially than after simple
glucose challenge (Figure 3C). We speculate that these effects
are due to the increased BA flux triggered by the test meal as
compared to the glucose challenge. In line with this hypothesis,
the treatment of ileal explants from TGR5-Tg and control mice
with lithocholic acid (LCA) confirmed that BAs provide an excel-
lent signal to induce GLP-1 release in the context of high TGR5
expression (Figure 3D). These data are furthermore in accor-
dance with results obtained in mTGR5-transfected STC-1 cells
in which GLP-1 release was also boosted by increased expres-
sion of TGR5 (Figure 2G). We speculate that in the context of
wild-type ileal explants, the quick degradation of GLP-1 by
DPP4 enzyme might mask the moderate increase in GLP-1
release triggered by LCA.
The impact of GLP-1 on pancreatic function has been exten-
sively documented during the last decade and ranges from
insulin-secretagogue effects to the promotion of pancreatic islet
survival and proliferation (Drucker, 2006). In this context, immu-
nofluorescent staining of insulin on pancreatic sections revealed
that, in contrast to hypertrophic islets with low insulin content, as
observed in HF-fed control mice, islets of HF-fed TGR5-Tg mice
were not hypertrophic and stained more intensively for insulin
(Figure 3E). In line with these data, counting and sizing of pancre-
atic islets confirmed that TGR5 expression results in the mainte-
nance of a normal islet distribution profile (Figure 3F), likely due
to enhanced plasma GLP-1 levels. In addition, the insulin content
of isolated pancreatic islets was significantly higher in HF-fed
TGR5-Tg mice than in controls (Figure 3G).
To further establish a role of TGR5 signaling in the mainte-
nance of glucose homeostasis, we assessed the glucose toler-
ance of germline TGR5-deficient mice (TGR5/), generated by
breeding mice in which the TGR5 allele was floxed with CMV-
Cre transgenic mice (Figures S4C–S4F). In direct contrast withCell Mwhat was observed in TGR5-Tg mice, glucose tolerance was
impaired in TGR5/ mice challenged with a HF-diet for 8 weeks
(Figure 3H), whereas no difference was observed in CD-fed mice
(data not shown). GLP-1 secretion was then tested by chal-
lenging TGR5+/+ and TGR5/ mice with an oral glucose load
30 min after the administration of saline or INT-777 alone, or in
combination with the DPP4 inhibitor (DPP4i), sitagliptin. Pread-
ministration of INT-777 moderately increased GLP-1 release
after a glucose challenge in TGR5+/+ mice (Figure 3I). This effect
was, however, markedly more pronounced when DPP4i was
coadministered as a consequence of its ability to prolong the
half-life of plasma GLP-1 (Drucker and Nauck, 2006) (Figure 3I).
In contrast, the effects of INT-777 on plasma GLP-1 levels were
blunted in TGR5/ mice (Figure 3J). Together, these data
underscore the critical role of TGR5 signaling in the control of
GLP-1 release and further demonstrate the specificity of the
semisynthetic agonist INT-777 in vivo.
The TGR5 Agonist INT-777 Increases Energy
Expenditure and Reduces Hepatic Steatosis
and Obesity upon High-Fat Feeding
In view of the improved glucose and insulin profile in TGR5-Tg
mice, we next assessed the therapeutic potential of INT-777
admixed at a dose of 30 mg/kg/day (mkd) with the diet in an inter-
vention study in C57BL/6J mice in which diabesity was induced
by HF feeding for 14 weeks. As expected, the HPLC profile of
plasma BAs confirmed the presence of INT-777 in the treated
mice only (Figure 4A). The plasma levels of INT-777 were within
the range of those of CA and b-muricholic acid (Figure S6A). It is
noteworthy that INT-777 treatment affected neither plasma BA
composition nor the expression profile of the enzymes involved
in BA synthesis, whose expression is mainly under the control
of nuclear receptors (Figures S6A and S6B). The complete
absence of changes in the expression level of classical target
genes of FXR in the liver, such as cholesterol 7a hydroxylase
(CYP7A1) and bile salt export pump (BSEP) (Thomas et al.,
2008), further confirmed the specificity of INT-777 toward
TGR5 (Figure S6B).
After 10 weeks of treatment with INT-777, a significant atten-
uation of body weight gain of about 15%, in association with a
sharp reduction in fat mass, was observed in HF-fed INT-777-
treated mice relative to HF-fed controls (Figures 4B and 4C).
The increase in liver and fat pad mass was also attenuated in
HF-fed INT-777-treated mice (Figure 4D). As noticed in our
previous study with CA (Watanabe et al., 2006), the decrease
in BAT mass was related to a diminution of white adipose tissue
(WAT) in the interscapular region (Figure 4D and data not shown).
The metabolic changes between control HF-fed and INT-777-
treated HF-fed mice were not caused by a reduced calorie intake
(Figure 4E) or fecal energy loss (Figure S6C), but rather were the
consequence of enhanced energy expenditure, as indicated by
the measurement of O2 consumption and CO2 production during
indirect calorimetry (Figure 4F). During the dark period, the respi-
ratory quotient of INT-777-treated mice was significantly re-
duced, consistent with increased fat burning (Figure 4F). Gene
expression profiling of BAT confirmed that activation of the
TGR5 signaling pathway triggers the increase of several mito-
chondrial genes involved in energy expenditure along with an
induction of type 2 deiodinase gene expression (Figure 4G).etabolism 10, 167–177, September 2, 2009 ª2009 Elsevier Inc. 171
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TGR5 Activation Prevents Metabolic DisordersFigure 4. The TGR5 Agonist INT-777 Increases Energy Expenditure and Reduces Hepatic Steatosis and Adiposity in DIO Mice
(A) Measurement by HPLC of plasma INT-777 levels in CD-, HF-, and HF-fed INT-777-treated male C57BL6/J mice.
(B) Dietary intervention with INT-777 (30 mg/kg/d) was started after a 14-week period of HF feeding at the time indicated by the arrow. Body weight evolution in all
groups was followed throughout the study (n = 8).
(C) Body composition was assessed by qNMR after 8 weeks of dietary intervention (n = 8).
(D) Organ mass was expressed as percent of the weight of CD-fed control mice.
(E) Food intake (n = 8).
(F) Spontaneous horizontal activity and energy expenditure, evaluated by the measurement of oxygen consumption (VO2) and carbon dioxide release (VCO2),
were monitored over a 18 hr period 6 weeks after the initiation of the dietary intervention. The respiratory quotient (RQ) was calculated as the ratio VCO2/
VO2. Bar graphs represent the average AUC. For the RQ, bar graphs represent the average (n = 8).
(G) Gene expression in BAT by real-time quantitative PCR after 18 weeks of dietary intervention. Target mRNA levels were normalized to 36B4 mRNA levels (n = 8).
(H) Primary brown adipocytes isolated from CD-fed C57BL/6J male mice were cultured for 12 hr with vehicle or 3 mM INT-777, and O2 consumption was measured
by using the XF24 extracellular flux analyzer (Seahorse Bioscience) (n = 5). The dotted lines illustrate the addition of the uncoupling agent FCCP at successive
doses of 250 and 500 nM.
(I) Representative pictures of oil red O (ORO) staining of cryosections (top panel) and Sirius red staining of paraffin-embedded sections (bottom panel) of the liver
at the end of the dietary intervention. Fibrosis is indicated by the arrow.
(J) Lipid content in liver samples extracted according to Folch’s method (n = 8).
(K and L) Plasma levels of liver enzymes (K) and lipids (L) at the end of the dietary intervention (n = 8). The data are represented as the mean ± SE. Student’s
unpaired t test; *p < 0.05, HF-fed compared to HF-fed INT-777-treated mice; and #p < 0.05, HF-fed versus CD-fed mice.The activation of the mitochondrial respiratory chain by INT-777
was further evidenced by measuring O2 consumption in primary
brown adipocytes isolated from C57BL/6J mice treated for 12 hr
with INT-777. Addition of the uncoupling agent, carbonylcya-
nide-ptrifluoromethoxyphenylhydrazone (FCCP), boosted basal
O2 consumption in all conditions but was significantly more
pronounced in those treated with INT-777 (Figure 4H). In addition
to the enhanced energy expenditure, liver function was also
improved, as evidenced by the reduction in liver steatosis, which
was assessed by oil red O staining (Figure 4I) and biochemical
quantification of liver lipid content (Figure 4J). Moreover, plasma
levels of liver enzymes were markedly reduced compared to172 Cell Metabolism 10, 167–177, September 2, 2009 ª2009 ElsevieHF-fed controls, correlating with the absence of liver fibrosis in
liver sections of INT-777-treated mice stained with Sirius red
(Figures 4I and 4K). The improvement in liver function was also
reflected by the significant drop in plasma triglycerides and
nonesterified fatty acids (NEFAs) in HF-fed mice treated with
INT-777 (Figure 4L).
The TGR5 Agonist INT-777 Improves Insulin Sensitivity
in Obese Mice
We also ascertained the ability of INT-777 to improve glucose
homeostasis. In both DIO and db/db mice, an environmental
and genetic model of diabesity, respectively, treatment withr Inc.
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TGR5 Activation Prevents Metabolic DisordersFigure 5. The TGR5 Agonist INT-777 Improves Insulin Sensitivity
in Obese Mice
(A) OGTT in CD- and HF-fed male C57BL6/J mice supplemented with 30 mg/
kg/d INT-777 for 8 weeks following the onset of obesity induced by feeding
a HF diet during 10 weeks. The inset represents the average AUC. Body weight
of vehicle and INT-777 treated mice was 38.08 ± 1.83 g and 32.26 ± 0.95 g,
respectively (n = 8; p < 0.05).
(B) Fasting glycemia and insulinemia (4 hr fasting) in DIO mice after 3 weeks of
dietary intervention with INT-777 (top panel). Plasma insulin levels during
OGTT in DIO mice (bottom panel).
(C) OGTT in 14-week-old CD-fed db/db male mice treated with 30 mg/kg/
d INT-777 for 6 weeks. The inset shows the average AUC (n = 8).
(D) Fasting (4 hr) glycemia and insulinemia in db/db mice after 6 weeks of treat-
ment with INT-777 (top panel). Plasma insulin levels during OGTT in DIO mice
(bottom panel).
(E) Insulin sensitivity evaluated through the average glucose infusion rate at
equilibrium (euglycemia) in a hyperinsulinemic euglycemic clamp (10 mU
insulin/min/kg) in DIO mice (following the onset of obesity induced by feeding
a HF diet during 10 weeks) after 10 weeks of dietary intervention with INT-777
(30 mg/kg/d) (n = 5). The evaluation of liver glucose production and its suppres-
sion by insulin, as well as the rate of glucose disappearance, was assessed at
equilibrium using 3H-glucose (n = 5).
(F) Insulin-stimulated glucose uptake in the indicated tissues was measured by
using 14C-2-deoxyglucose tracers (n = 5).
(G) Gene expression profiling in liver was performed by real-time quantitative
PCR. Target mRNA levels were normalized to 36B4 levels (n = 8). The dataCell MINT-777 (30 mkd) admixed with the diet robustly improved
glucose tolerance after an oral challenge with glucose (Figures
5A and 5C), along with an improvement of the glucose-stimu-
lated insulin secretion profile (Figures 5B and 5D, lower panel).
This feature is consistent with a GLP-1-mediated improvement
in pancreatic function. Furthermore, fasting glucose and insulin
levels were decreased in both DIO and db/db mice that were
treated with INT-777 (Figures 5B and 5D, top panel). To further
characterize the impact of INT-777 on glucose homeostasis
and insulin sensitivity, a hyperinsulinemic euglycemic glucose
clamp was performed on these DIO mice. Consistent with the
improved glucose tolerance, the glucose infusion rate required
to maintain euglycemia in DIO mice treated with INT-777 was
virtually identical to that observed in CD-fed control mice
(Figure 5E). While insulin-resistant HF-fed mice showed an
increased endogenous production of hepatic glucose, together
with a reduction of both glucose disposal rate and the suppres-
sion of glucose production by insulin, INT-777 treatment of
HF-fed mice normalized these parameters to the values
observed in CD-fed mice (Figure 5E). Measurement of insulin-
stimulated 14C-deoxyglucose uptake during the hyperinsuline-
mic euglycemic glucose clamp indicated that the improvement
in glucose homeostasis by INT-777 could be mainly attributed
to reduced insulin resistance in liver and muscle (Figure 5F).
These effects correlated with normalization in the expression of
key genes involved in hepatic glucose homeostasis (Figure 5G).
To address the specificity of INT-777 with regard to TGR5
in vivo, the impact of 4 weeks’ treatment with INT-777 at
30 mkd on glucose tolerance was compared in TGR5+/+ and
TGR5/ mice, primed by HF feeding for 9 weeks. Even over
this short time period, INT-777 significantly improved glucose
tolerance in TGR5+/+ fed a HF diet (Figure 6A), along with a
normalization of insulin secretion during oral glucose challenge
(Figure 6B). These effects were blunted in TGR5/ mice,
thereby providing further arguments to support the specificity
of INT-777 for TGR5 (Figures 6A and 6B).
DISCUSSION
Following our previous demonstration that TGR5 activation
governs energy metabolism in BAT and muscle (Watanabe
et al., 2006), and inspired by the fact that TGR5 is expressed in
enteroendocrine cells (Katsuma et al., 2005; Reimann et al.,
2008), we explored in this study whether TGR5 activation could
alter glucose homeostasis. Our data demonstrate that GLP-1-
producing enteroendocrine cells are sensitive not only to nutri-
ents present in the intestinal lumen, such as glucose and lipids
(Edfalk et al., 2008; Hirasawa et al., 2005; Overton et al., 2006;
Reimann et al., 2008), but also to BAs, that activate the TGR5
signaling pathway. Along with the lipid-sensing GPCRs,
GPR40, GPR119 and GPR120 (Edfalk et al., 2008; Hirasawa
et al., 2005; Overton et al., 2006; Reimann et al., 2008), TGR5
represents a key pathway for the regulation of intestinal GLP-1
release. TGR5-mediated GLP-1 release in enteroendocrine L
cells involves the closure/opening of the KATP/Cav channels
are represented as mean ± SE. Student’s unpaired t test; *p < 0.05, HF-fed
compared to HF-fed INT-777 treated mice; and #p < 0.05, HF-fed versus
CD-fed mice.etabolism 10, 167–177, September 2, 2009 ª2009 Elsevier Inc. 173
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and the subsequent change in ATP/ADP ratio. Modulating this
TGR5-driven pathway is of therapeutic potential, given that in-
cretin-based therapies have emerged as potent antidiabetic
strategies (Drucker, 2006; Drucker and Nauck, 2006).
In addition to our observations on GLP-1 release in vitro, we
demonstrated through a gain- and loss-of-function genetic
approach that the TGR5 pathway is a crucial determinant of
glucose homeostasis in vivo. In fact, the activation of TGR5 by
the selective and potent TGR5 agonist INT-777 may constitute
a way to stimulate the release of incretins, such as GLP-1, trans-
lating into beneficial metabolic effects that could be of use in the
treatment of diabesity and associated metabolic disorders.
Although the receptor is expressed in many tissues (Kawamata
et al., 2003; Maruyama et al., 2002), activation of TGR5 with
the CA-derived INT-777 is particularly attractive, given the
increased exposure of enteroendocrine cells in the gut due to
the extensive enterohepatic recirculation of INT-777 with other
BAs in the bile pool (data not shown). In this manner, the effi-
ciency of intestinal BA reabsorption considerably increases the
effective dose to which enteroendocrine cells are exposed.
Figure 6. INT-777-Mediated Improvement of Glucose Tolerance
Is TGR5 Dependent
(A) TGR5+/+ and TGR5/ male mice were fed a HF diet for 9 weeks, and a first
OGTT was performed thereafter. HF was then supplemented with INT-777 at
30 mg/kg/d. A second OGTT was performed 4 weeks after treatment with
INT-777 was initiated. Curves represent glucose tolerance before and after
4 weeks’ treatment with INT-777 in TGR5+/+ (left panel) and TGR5/ (right
panel) mice. The inset represents the average AUC. In TGR5+/+ mice, body
weight before and after INT-777 treatment was 46.86 ± 3.54 g and 43.50 ±
3.47 g, respectively (n = 8; not statistically different). In TGR5/ mice, body
weight before and after INT-777 treatment was 54.34 ± 2.23 g and 52.30 ±
2.72 g, respectively (n = 8; not statistically different).
(B) Plasma insulin levels were concurrently measured during the OGTT in DIO
in TGR5+/+ (left panel) and TGR5/ (right panel) mice before and after 4 weeks’
treatment with INT-777. The inset represents the average AUC (n = 8). The data
are represented as mean ± SE. Student’s unpaired t test; *p < 0.05, vehicle
compared to INT-777-treated mice.174 Cell Metabolism 10, 167–177, September 2, 2009 ª2009 ElsevieDespite these ‘‘gut-centered’’ properties of BAs and their deriv-
atives, we cannot exclude the possibility that some of the bene-
ficial metabolic actions of INT-777 may be unrelated to its modu-
lation of GLP-1 levels. It is interesting to note within this context
that other GPCRs expressed in enteroendocrine cells, such as
GPR119 (Chu et al., 2007), are also expressed in pancreatic
b cells (Chu et al., 2007; Sakamoto et al., 2006; Soga et al.,
2005). We can therefore at present not ascertain that some
TGR5-mediated effect on insulin release and glucose tolerance
could involve direct pancreatic effects that are partially indepen-
dent of GLP-1. Further investigations, using a b cell-specific
TGR5-deficient mouse model, are required to test this assump-
tion.
It should also be noted that, given the systemic bioavailability
of INT-777 as evidenced by the plasma concentrations
achieved, direct activation of TGR5 in other tissues is also a
significant factor in the compound’s effects in vivo. Indeed, in
line with our previous experience with natural BAs (Watanabe
et al., 2006), INT-777 also increased energy expenditure and
attenuated weight gain upon high-fat feeding through TGR5-
mediated effects in BAT and muscle. The more-limited impact
of INT-777 on energy expenditure relative to our previous study
using natural BAs can be attributed to the substantially lower
doses of INT-777 that were administered in this study. Since
the TGR5 signaling pathway has also been shown to be active
in macrophages, further investigation is also required to evaluate
the potential ameliorative effect of INT-777 on inflammatory
processes, which also contribute to the metabolic syndrome
(Despres and Lemieux, 2006).
Our current work also underscores the complexity of the endo-
crine activities of BAs, including TGR5- and FXR-mediated
actions, which all integrate to maintain glucose homeostasis.
TGR5-mediated effects of BAs appear to center on the stimula-
tion of GLP-1 release and the subsequent improvement in insulin
secretion and pancreatic function (Drucker, 2006; Drucker and
Nauck, 2006). BAs that escape the first-pass hepatic clearance
and end up in the systemic circulation (Angelin et al., 1982)
then fine-tune energy expenditure through activation of TGR5
in BAT and muscle with a resulting attenuation of weight gain
(Watanabe et al., 2004). By contrast, so far no significant weight
loss has been reported in the context of FXR activation in mice
(Duran-Sandoval et al., 2005; Ma et al., 2006; Watanabe et al.,
2006; Zhang et al., 2006). Instead, FXR-mediated actions of
BAs appear mainly to affect liver metabolism by increasing
glycogen production (Duran-Sandoval et al., 2005; Ma et al.,
2006; Zhang et al., 2006) and decreasing lipogenesis and
VLDL production (Watanabe et al., 2004), thereby reducing
hepatic glucose and fatty acid output, which in turn contributes
to improved insulin sensitivity (Duran-Sandoval et al., 2005; Ma
et al., 2006; Zhang et al., 2006).
The link between BAs and glucose homeostasis may be rele-
vant not only in mice but also in humans. In support of this
hypothesis, a correlation between BA levels and insulin sensi-
tivity has already been evidenced in humans (Shaham et al.,
2008). Interestingly, plasma BA levels were also found to be
significantly higher in subjects after bariatric surgery than in
matched obese patients, suggesting that BAs may contribute
to the metabolic improvements of weight loss surgery (Patti
et al., 2009). The inverse relationship between total BAr Inc.
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positive correlation between BAs and peak GLP-1 in that study,
further indicates that also in humans BAs may be key regulators
of GLP-1 release and glucose homeostasis (Patti et al., 2009).
In conclusion, by employing a combination of pharmacolog-
ical and genetic gain- and loss-of-function genetic approaches,
our studies show that the activation of the TGR5 signaling
pathway counteracts the metabolic dysfunction associated
with diabesity. TGR5 activation results in a range of beneficial
metabolic effects that include resistance to weight gain and
hepatic steatosis, preservation of liver and pancreatic function,
and the maintenance of glucose homeostasis and insulin sensi-
tivity. These effects are due to enhanced mitochondrial function
in muscle, BAT, and enteroendocrine cells, resulting in an
increase in energy expenditure and incretin secretion (Figure 7).
This leads us to conclude that TGR5 agonists could represent
potential promising agents for the management of diabesity,
along with associated disorders such as nonalcoholic steatohe-
patitis (NASH).
EXPERIMENTAL PROCEDURES
Chemicals and Reagents
All biochemical reagents were purchased from Sigma-Aldrich unless indi-
cated. The DPP4 inhibitor (DPP4i) sitagliptin was a kind gift from Dr. C. Ullmer
(Hoffmann-La Roche). INT-777 was synthesized as previously described
(Macchiarulo et al., 2008; Pellicciari et al., 2007).
Cell Culture
In vitro experiments were carried out in STC-1 or NCI-H716 cells treated with
vehicle (DMSO) or INT-777. INT-777 was assessed for its agonistic activity on
TGR5 as previously described (Macchiarulo et al., 2008; Pellicciari et al., 2007).
cAMP production was performed as described (Sato et al., 2008; Watanabe
et al., 2006). Cox activity was evaluated by following the oxidation of fully
reduced cytochrome c (Sigma) at 550 nm (Feige et al., 2008b). ATP/ADP ratio
Figure 7. TGR5-Mediated BA Sensing Maintains Metabolic Function
In BAT (mouse) and in skeletal muscle (human), TGR5 activation triggers an
increase in mitochondrial oxidative phosphorylation (OXPHOS), which results
in energy expenditure and helps prevent obesity in mice treated with TGR5
agonists. Here we demonstrated that in enteroendocrine L cells, TGR5 activa-
tion also triggers an increase in mitochondrial OXPHOS, which is associated
with a rise in the ATP/ADP ratio and a subsequent closure of the ATP-depen-
dent potassium channel (KATP) and calcium mobilization (Cav). As a conse-
quence, release of the incretin glucagon-like peptide-1 (GLP-1) is increased,
which helps explain the improvement of glucose homeostasis in obese mice
treated with a TGR5 agonist.Cell Meand GLP-1 release were measured according to the manufacturers’ instruc-
tions (Biovision and Millipore, respectively). Primary brown adipocytes were
prepared as previously described (Watanabe et al., 2006), and ileal explants
were prepared according to an established method (Cima et al., 2004).
Intracellular Calcium Quantification
NCI-H716 (40,000 cells) was seeded in 96-well black plates coated with Matri-
gel (BD Biosciences). Seventy-two hours after transfection, cells were washed
twice in assay buffer (HBSS1x, 20 mM HEPES [pH 7.4]) and assayed for intra-
cellular calcium with Fluo-4 AM according to the manufacturer’s protocol
(Invitrogen).
Biochemistry and Histochemistry
Plasma parameters and hepatic and fecal lipid content were measured as
described (Mataki et al., 2007). Hematoxylin and eosin (H&E), Sirius red, and
oil red O staining were performed as described (Mark et al., 2007), and micro-
graphs were taken on wide-field microscopes (Leica) with a CCD camera. For
pancreatic sections, islets were sized and counted from four HE-stained alter-
nated sections spaced of 150 mM using ImageJ software (five animals per
group). Immunofluorescent staining of insulin was performed as described
(Fajas et al., 2004). Additionally, pancreatic islets were isolated by collagenase
digestion of pancreas from HF-fed TGR5-Tg mice according to online-avail-
able procedures (http://www.jove.com/index/Details.stp?ID=255). Insulin
was extracted after O/N incubation at 20C in acid ethanol and measured
by ELISA on PBS-diluted samples according to the manufacturer’s instruc-
tions (Mercodia). GLP-1 release was measured in vitro, ex vivo, and in vivo
as described in the Supplemental Experimental Procedures.
Oxygen Consumption Measurement
Cellular oxygen consumption was measured using a Seahorse Bioscience
XF24 analyzer with ten biological replicates per condition (Feige et al., 2008b).
Animal Experiments
Animals were housed and bred according to standardized procedures (Arg-
mann and Auwerx, 2006b). Age-matched male mice were used for all experi-
ments. Genetically engineered mouse models (GEMMs), i.e., TGR5-Tg and
TGR5/ mice, were generated as described in the Supplemental Data. DIO
in the GEMMs or C57BL/6J mice (Charles River) was induced by feeding
8-week-old mice with a HF diet (60% cal/fat, D12492; Research Diets) for at
least 8 weeks, as mentioned in the text and figure legends. In the dietary inter-
vention experiments, INT-777 was mixed with diet (Feige et al., 2008a) at the
dose sufficient to reach an in vivo dose of 30 mg/kg/d. Mouse phenotyping
experiments were performed according to EMPRESS protocols (http://
empress.har.mrc.ac.uk) and were aimed to assess food and water intake,
body composition (Argmann et al., 2006a), energy expenditure (Argmann
et al., 2006a), glucose and lipid homeostasis (Argmann et al., 2006b; Heikkinen
et al., 2007; Mataki et al., 2007), and plasma biochemistry (Argmann and
Auwerx, 2006a). Tissues and blood were collected and processed for histopa-
thology, blood chemistry, and gene expression according to standardized
procedures (Argmann and Auwerx, 2006a; Feige et al., 2008b; Mark et al.,
2007; Watanabe et al., 2006). Hyperinsulinemic euglycemic clamp studies
were performed as described (Feige et al., 2008b), with minor modifications
including a change in the initial insulin bolus (30 mU/kg) and insulin infusion
rate (10 mU/min/kg). Plasma GLP-1 levels were measured by ELISA (Millipore)
on blood collected by retro-orbital puncture. Experiments with db/db mice
(Charles River) were performed in 14-week-old animals fed a CD without or
with INT-777 (30 mg/kg/d) for 6 weeks (Feige et al., 2008a).
Gene Expression Profiling
Gene expression profiling was performed by real-time quantitative PCR
(Feige et al., 2008b; Watanabe et al., 2006). Primer sequences used have
been previously published, except those used for the Kir6.2 gene: R-50
AGATGCTAAACTTGGGCTTG, F-50 TAAAGTGCCCACACCACTC.
Statistics
Statistical analyses were performed by using the unpaired Student’s t test.
Data are expressed as mean ± SEM, and P values smaller than 0.05 were
considered statistically significant.tabolism 10, 167–177, September 2, 2009 ª2009 Elsevier Inc. 175
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and Supplemental References and can be found with this article online at http://
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